Slide 1: Exchange filing cover letter: Investor Presentation Q1 FY24
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/AJ/2023-24/72 August 11, 2023 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Cor
Slide 2: Q1 FY24 Investor Presentation
Q1 FY24 Investor Presentation August 2023
Slide 3: Core Values
Biocon is a technology-enabled, future-ready, global biopharmaceuticals leader driven by an unwavering purpose to enhance healthcare worldwide through high- quality, affordable therapies that can lower costs, increase access and improve treatment outcomes. Value Creation through Innovation & Differe
Slide 4: Biocon at a Glance
Biocon at a Glance ₹ 11,550 Cr | ~16,500+ Rank #8 Among Top 10 Global Total Employees* $ ~1.4 bn Biotech Employers** Revenue* 1,500+ 100+ 7 Patents* cGMP approvals from International regulatory agencies Manufacturing units* 120+ 15 of top 20 Top 28 Countries where our pharma companies Products withi
Slide 5: Building Biocon
Building Biocon
Slide 6: Biocon: One Company, with multiple value propositions across its verticals
Biocon: One Company, with multiple value propositions across its verticals From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality & affordable healthcare products & services, globally Ensuring access through quality, affordability, reliability ▪ Lead
Slide 7: Generics Business at a Glance
Generics Business at a Glance Presence in R&D team of 6 90+ 750+ 100+ State-of-the-art cGMP approvals 450+ global countries including U.S., manufacturing received from international scientists customer reach Europe & large EMs sites regulatory agencies Portfolio comprises 90+ 500+ 300+ 50+ APIs Gene
Slide 8: Generics: API & Formulations - Growth Levers
Generics : API & Formulations - Growth Levers Strengths built over the years Product Portfolio Expansion Capacities Additions & Expansion • Expertise in fermentation technology, large scale • API - Expanding portfolio beyond fermentation and • Immunosuppressants API (Visakhapatnam) chromatography &
Slide 9: Generics: Our Key APIs and Formulations
Generics : Our Key APIs and Formulations APIs* F O R M U L AT I O N S Therapeutic Therapeutic Area Molecule Molecule Therapeutic Area Molecule US Dev. Markets: ex-US MoW1 Area Tacrolimus Rosuvastatin Calcium EU Apixaban Simvastatin Atorvastatin Mycophenolate Mofetil Atorvastatin Dabigatran Cardiovas
Slide 10: Biosimilars Business at a Glance
Biosimilars Business at a Glance Global reach in Diverse global Top 15 85+ 100+ in global cGMP approvals talent pool of countries including U.S., biomanufacturing received from key regulatory 5,500+ Europe and EMs capacity agencies people 390+ Portfolio comprises 8 patents granted 20 biosimilars Com
Slide 11: Biosimilars: Unique, fully integrated capabilities from lab to market
Biosimilars: Unique, fully integrated capabilities from lab to market Research & Development Global Scale Manufacturing Commercialization Process & Product Development Mammalian & microbial tech platforms Commercial footprint in 100+ countries 3 Manufacturing Sites Analytical & Bioanalytical Capabil
Slide 12: Biosimilars: Leading global player with a strong track record of success
Biosimilars: Leading global player with a strong track record of success Built on a 40+ year legacy of cutting-edge science …with a strong track record in an attractive market • Invested >$1B in biosimilars ahead of its peers to build • Achieved many ‘firsts’ in the industry - first to receive exper
Slide 13: Biosimilars: Acquisition of Viatris' global biosimilars business
Biosimilars: Acquisition of Viatris’ global biosimilars business Provides full Accelerates BBL’s ownership direct entry in of collaboration many markets assets, as well as across AMs & EMs, Viatris’ rights for in- takes us closer to licensed biosimilars USD 3B+ Acquisition - Amongst Largest patients
Slide 14: Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars
Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars Oncology Immunology Ophthalmology Bone Health Diabetes Others Therapy Area • Pegfilgrastim • Adalimumab • RHI Approved or • Trastuzumab • Etanercept • Glargine U100 Commercial • Bevacizumab • Aspart • Denosumab • Ustekinumab •
Slide 15: Novel Molecules: Itolizumab
Novel Molecules: Itolizumab Pushing to deliver impactful innovations in collaboration with Equillium Inc. ✓ Pivotal Phase III Study initiated in Mar ’22 for use in First-Line treatment of Acute GVHD; Acute Graft- patient dosing initiated Itolizumab Versus-Host ✓ European Commission granted Orphan Dr
Slide 16: Novel Molecules: Bicara Therapeutics - BCA101
Novel Molecules: Bicara Therapeutics* - Dual Action | Dual Impact The precision of targeted therapies | The power of tumor modulators ✓ Lead product candidate, BCA101 (EGFR / TGF-β-trap) demonstrates tumor target engagement and clinical activity ✓ Monotherapy activity in difficult to treat post-pemb
Slide 17: Syngene's broad capabilities spanning the value chain
Syngene’s broad capabilities, spanning the value chain, facilitate integration to captures additional benefits for clients Research business Development and Manufacturing business Discovery Services Dedicated R&D Centers Development Services Manufacturing Services Flexible Platform with capability a
Slide 18: Syngene: Strategic Priorities
Syngene: Strategic Priorities Research: Research: Discovery Services Dedicated Centers Operational Excellence Provide end-to-end therapeutic Continue to strengthen our existing Focus on customer delivery discovery capabilities including partnerships with Amgen, Bristol through operational excellence
Slide 19: Q1 FY24 Highlights
Q1 FY24 Highlights
Slide 20: Financial Highlights: Q1 FY24
Financial Highlights: Q1 FY24 Consolidated (in ₹ Cr.) Q1 FY24 Q1 FY23 YoY % Total Revenue 3,516 2,217 59 Biosimilars +106% | Research +25% | Generics 15% Core EBITDA1 936 661 42 Growth across Generics, Biosimilars & Research Services % Margin 28% 31% Net R&D spend at ₹315 Cr, up ₹117 Cr vs Q1 FY23,
Slide 21: Biocon Generics: Q1 FY24 Highlights
Biocon Generics: Q1 FY24 Highlights Revenue growth driven primarily by U.S. generic formulations business; new product launches in key ex-US markets In INR Cr Q1 FY24 Q1 FY23 YoY % Continued traction in immunosuppressant API portfolio Segment Revenue 700 607 15 PBT 64 63 1 Received ‘Tentative Approv
Slide 22: Biocon Biologics: Biosimilars – Q1 FY24 Business Update
Biocon Biologics: Biosimilars – Q1 FY24 Business Update Key Products’ Market Share1 Significant growth in market shares of key commercial products United States Jun-23 Jun-22 Fulphila (bPegfilgrastim) 16% 8% Increase in NRx to 15% for Insulin Glargine in the U.S., demonstrates Ogivri (bTrastuzumab)
Slide 23: Biocon Biologics: Biosimilars – Q1 FY24 Financial Update
Biocon Biologics: Biosimilars – Q1 FY24 Financial Update Revenues doubled Y-o-Y with driven by increased market share and In INR Cr Q1 FY24 Q1 FY23 YoY % consolidation of Viatris’ biosimilar business Revenue 2,015 977 106 Core EBITDA1 513 361 42 Sequentially, revenues largely flat due to phasing of
Slide 24: Novels: Q1 FY24 Update
Novels: Q1 FY24 Update Patient enrolment ramped up in the pivotal Phase III clinical study of itolizumab in patients with aGVHD* (EQUATOR study) Pivotal Phase 1b clinical study of Itolizumab for Lupus Nephritis (EQUALISE study) fully enrolled. Top line data expected in 1H2024 BCA101 demonstrates 65%
Slide 25: Syngene: Q1 FY24 Update
Syngene: Q1 FY24 Update Strong performance led by Development and Manufacturing Services; supported by sustained growth in Discovery Services and the Dedicated In INR Cr Q1 FY24 Q1 FY23 YoY % Centers Revenue 808 645 25 Announced deal to acquire multimodal biologics plant from Stelis along with PBT 1
Slide 26: Environment, Social, Governance
Environment, Social, Governance
Slide 27: ESG: A Culture of Purpose, Ethics & Equity
ESG: A Culture of Purpose, Ethics & Equity Going beyond financials to have a positive impact Recognitions Our ESG Strategy Pillars Published 1st GRI aligned Integrated Report & 2nd BRSR Report for FY23 Improve access to high quality therapeutics to drive ‘Patient Equity’ Improved ESG score of 52, pa
Slide 28: Progressed to Integrated Reporting
Progressed to Integrated Reporting Continuously improving disclosures towards better transparency 1st GRI aligned Integrated Report for FY23 with many maiden disclosures Outcome of Gender Pay Gap Analysis Alignment with TCFD Outcome of Water Risk Assessment Outcome of Biodiversity Impact Assessment
Slide 29: Annexures
Annexures
Slide 30: Biocon's Evolution: Our journey over the last 5 decades
Biocon’s Evolution: Our journey over the last 5 decades Metamorphosis from manufacturer of enzymes to a vertically integrated bio-pharmaceutical player and global CRO & CDMO of global standing. Created tangible differentiators for sustainable growth with focus on research and innovation 1970s-80s 19
Slide 31: With many firsts, Biocon is ahead of the curve
With many firsts, Biocon is ahead of the curve • 1st Indian Life • 1st Clinical Research • 1st company globally to • 1st company in the • 1st Indian Company • 1st anti-CD6 Sciences Company Service Organization get U.S. FDA approval world to develop & to launch a novel monoclonal antibody to get ISO
Slide 32: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 33: Thank You
Thank You $ Biocon 4 on iS hares @> ye. Rote re Oc ee ee oe tet oe, ete e ra sly . we ee wt “ete eS. Cy “ : Aw** Relentless Pursuit. Differentiated Growth. O~» 32